Jingfeng Pharmaceutical(SZ:000908)2024-07-09 10:29Group 1: Company Restructuring and Management - On April 22, 2024, Hunan Jingfeng Pharmaceutical Co., Ltd. received a notice from creditor Peng Dongju regarding the application for pre-restructuring and restructuring due to the company's inability to repay debts and lack of repayment capacity [3] - The court has initiated a pre-restructuring process for the company, which will last for three months, with a possible one-month extension if justified [3][4] - The pre-restructuring aims to facilitate early engagement with creditors and potential investors, improving the efficiency and success rate of subsequent restructuring efforts [3] Group 2: Management Changes - On July 3, 2024, the company announced the resignation of Chairman Ye Xiangwu and Vice President Bi Yuan due to work adjustments, effective immediately upon submission of their resignation reports [5] - Zhang Li has been appointed to temporarily assume the duties of Chairman and Secretary of the Board until a new Chairman is elected [5] Group 3: Risk Management and Oversight - Morgan Stanley Securities will continue to monitor the situation closely and ensure that the company secures funds for the repayment of the "16 Jingfeng 01" bonds, adhering to relevant regulations and agreements [7] - Investors are advised to remain aware of the associated risks regarding the company's restructuring and management changes [6]